Articles related to IMMUNOTHERAPY

“The enrichment of diverse immune‐related pathways in the HIC cluster suggests that these patients could be prime candidates for future immunotherapy strategies.”

“By disabling Ant2, we triggered a complete shift in how T cells produce and use energy. This reprogramming made them significantly better at recognizing and killing cancer cells.”

“Myeloid cells are among the first group of immune cells recruited to tumors, but very quickly these tumor-fighting cells turn into tumor-supporting cells.”

“This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.” — Norman Sharpless, MD

Patients receiving pembrolizumab before, during, and after surgery demonstrated longer event-free survival and higher substantial tumor shrinkage rates, with median survival extending from 30.4 to 51.8 months compared to standard care alone.

Global phase 3 study randomized patients with platinum-refractory extensive-stage SCLC to first-in-class bispecific immunotherapy versus regional standard chemotherapy, achieving primary overall survival endpoint with consistent safety profile.